Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Abhijit Agarwal"'
Autor:
Richard T. Maziarz, Jie Zhang, Hongbo Yang, Xinglei Chai, Chengbo Yuan, Elisabeth Schwarz, Mihael Jakovac, Marcela Martinez-Prieto, Abhijit Agarwal, Evgeny Degtyarev, Constantine Tam, Gilles Salles
Publikováno v:
Blood Advances. 6:2536-2547
No head-to-head trials have compared the efficacy of tisagenlecleucel vs historical treatments for adults with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). This study indirectly compared the overall survival (OS) and overall resp
Autor:
Ulrich Jaeger, Constantine S. Tam, Peter Borchmann, Joseph P. McGuirk, Marianne Johansen, Edmund K. Waller, Samantha Jaglowski, Charalambos Andreadis, Stephen R. Foley, Jason R. Westin, Isabelle Fleury, P. Joy Ho, Stephan Mielke, Takanori Teshima, Gilles Salles, Stephen J. Schuster, Fiona He, Richard T. Maziarz, Sebastian Mayer, Shinichi Makita, Marie J. Kersten, Monalisa Ghosh, Nina Wagner-Johnston, Koji Kato, Paolo Corradini, Hideki Goto, Silvia Colicino, Abhijit Agarwal, Chiara Lobetti-Bodoni, Michael R. Bishop
Publikováno v:
Jaeger, U, Tam, C S, Borchmann, P, McGuirk, J P, Johansen, M, Waller, E K, Jaglowski, S, Andreadis, C, Foley, S R, Westin, J R, Fleury, I, Ho, P J, Mielke, S, Teshima, T, Salles, G, Schuster, S J, He, F, Maziarz, R T, Mayer, S, Makita, S, Kersten, M J, Ghosh, M, Wagner-Johnston, N, Kato, K, Corradini, P, Goto, H, Colicino, S, Agarwal, A, Lobetti-Bodoni, C & Bishop, M R 2022, ' Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma ', Blood, vol. 6, no. 16, pp. 4816-4820 . https://doi.org/10.1182/bloodadvances.2021006193
Blood, 6(16), 4816-4820. American Society of Hematology
Blood advances, 6(16), 4816-4820. American Society of Hematology
Blood, 6(16), 4816-4820. American Society of Hematology
Blood advances, 6(16), 4816-4820. American Society of Hematology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::845b49630d97668467f6c44f77f474ae
https://research.vumc.nl/en/publications/d4cb09d4-1d54-4e76-8613-106f26f29173
https://research.vumc.nl/en/publications/d4cb09d4-1d54-4e76-8613-106f26f29173
Autor:
Hongbo Yang, Abhijit Agarwal, David Kuzan, Marcela Martinez-Prieto, Vamsi Bollu, Wenxi Tang, Marie-Jose Kersten, Richard T. Maziarz, Stephen J. Schuster, Jie Zhang
Publikováno v:
Hematological Oncology. 39
Autor:
Stephen J. Schuster, Jie Zhang, Hongbo Yang, Abhijit Agarwal, Wenxi Tang, Marcela Martinez-Prieto, Vamsi Bollu, David Kuzan, Richard T. Maziarz, Marie José Kersten
Publikováno v:
Leukemia & lymphoma. Informa Healthcare
Leukemia and Lymphoma, 63(4), 845-854. Informa Healthcare
Schuster, S J, Zhang, J, Yang, H, Agarwal, A, Tang, W, Martinez-Prieto, M, Bollu, V, Kuzan, D, Maziarz, R T & Kersten, M J 2022, ' Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas : an indirect treatment comparison ', Leukemia and Lymphoma, vol. 63, no. 4, pp. 845-854 . https://doi.org/10.1080/10428194.2021.2010069
Leukemia and Lymphoma, 63(4), 845-854. Informa Healthcare
Schuster, S J, Zhang, J, Yang, H, Agarwal, A, Tang, W, Martinez-Prieto, M, Bollu, V, Kuzan, D, Maziarz, R T & Kersten, M J 2022, ' Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas : an indirect treatment comparison ', Leukemia and Lymphoma, vol. 63, no. 4, pp. 845-854 . https://doi.org/10.1080/10428194.2021.2010069
This study compared overall survival (OS), progression-free survival (PFS), complete response rate (CRR), and overall response rate (ORR) of tisagenlecleucel (tisa-cel) and lisocabtagene maraleucel (liso-cel) in relapsed or refractory large B-cell ly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f91da64d2502024148cdecb9e24326e
https://pure.amc.nl/en/publications/comparative-efficacy-of-tisagenlecleucel-and-lisocabtagene-maraleucel-among-adults-with-relapsedrefractory-large-bcell-lymphomas(61ae7c8d-3442-49a9-a3da-bbedaa31280b).html
https://pure.amc.nl/en/publications/comparative-efficacy-of-tisagenlecleucel-and-lisocabtagene-maraleucel-among-adults-with-relapsedrefractory-large-bcell-lymphomas(61ae7c8d-3442-49a9-a3da-bbedaa31280b).html
Autor:
Amy K. Keating, Rayne H. Rouce, Paul L. Martin, Michael A. Pulsipher, Marcelo C. Pasquini, Amy Moskop, Ranjan Tiwari, Samuel John, Jennifer Willert, Christine L Phillips, Stephan A. Grupp, Benjamin Oshrine, Abhijit Agarwal, Sarah Nikiforow, Steven P. Margossian, Erin Marie Hall, Zhen-Huan Hu, Santiago Redondo
Publikováno v:
Blood. 138:428-428
Background: Tisagenlecleucel is an autologous CD19-directed T-cell immunotherapy indicated in the USA for treatment of patients up to 25 years (y) of age with B-cell ALL that is refractory or in second or later relapse. Overall response rate was 82%
Autor:
Stephen J. Schuster, Jie Zhang, Hongbo Yang, Abhijit Agarwal, Wenxi Tang, Marcela Martinez Prieto, Vamsi Bollu, David Kuzan, Richard Maziarz, Marie José Kersten
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S238
Autor:
Marcela Martinez-Prieto, Wenxi Tang, Vamsi Bollu, Hongbo Yang, Jie Zhang, Stephen J. Schuster, Richard T. Maziarz, Abhijit Agarwal, Marie José Kersten, David Kuzan, Qiufei Ma
Publikováno v:
Journal of Clinical Oncology. 39:7535-7535
7535 Background: Chimeric antigen receptor T-cell therapies tisa-cel and liso-cel are effective treatments for r/r DLBCL (Schuster 2019, Abramson 2020). This study compared efficacy outcomes of tisa-cel and liso-cel in r/r DLBCL using matching-adjust
Publikováno v:
Aging (Albany NY)
We tested the feasibility of setting individualized glycemic goals and factors influencing targets set in a clinical trial in elderly patients with type 2 diabetes. A 24-week, randomized, double-blind, placebo-controlled study was conducted in 45 out